[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kazakhstan Scientific Society for Study of intestine diseases\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100556326","clinical-efficacy-of-ustekinumab-in-crohns-disease-100556326",false,"NCT06523647","Clinical Efficacy of Ustekinumab in Crohn's Disease","Clinical Efficacy of Ustekinumab in Crohn's Disease: an Observational Study With Retrospective and Prospective Components","Inclusion Criteria:\n\n* Patients aged 18 years and older;\n* Patients who were first prescribed Ustekinumab between January 1 and December 31, 2024\n* Patients who provided written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Contraindications to the use of the drug Ustekinumab per the current instructions:\n\n  * Clinically significant active infection (active tuberculosis, active viral hepatitis);\n  * Pregnancy and lactation;\n  * A history of clinically significant, in the opinion of the investigator, psychiatric disorders that may interfere with the study procedures and compliance with the drug regimen;\n  * Ulcerative colitis;\n  * Malignant gastrointestinal diseases in history or at the time of inclusion in the study;\n  * Decompensated chronic diseases of the liver, kidneys, cardiovascular system, systemic vasculitis, diabetes mellitus;\n  * Abuse of alcohol or psychoactive drugs within 1 year before the start of this study (as reported by the patient);\n* Participation in an interventional clinical trial.","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","Clinical Efficacy of Ustekinumab in Crohn's Disease: an Observational Study With Retrospective and Prospective Components.",[24],"Crohn's Disease","RECRUITING","2024-07-23",{"date":28,"type":29},"2024-07-26","ACTUAL",{"date":31,"type":29},"2023-06-27",{"date":33,"type":20},"2025-12",{"name":35,"class":36},"Kazakhstan Scientific Society for Study of intestine diseases","OTHER",4,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":43,"conditions":48,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},"100555794","an-assessment-of-the-effectiveness-efficacy-of-odeston-odeston-in-patients-with-chronic-cholecystitis-in-real-medical-practice-100555794","NCT06516718","An Assessment of the Effectiveness (Efficacy) of Odeston (Odeston®) in Patients With Chronic Cholecystitis in Real Medical Practice","Post-marketing Observational Clinical Study: Assessment of the Effectiveness (Efficacy) of Odeston (Odeston®) in Patients With Chronic Cholecystitis in Real Medical Practice","Inclusion Criteria:\n\n* Men and women aged 18 to 65 years;\n* BMI 18.5 - 40;\n* Verified diagnosis: chronic acalculous cholecystitis;\n* Voluntary desire to provide informed consent to participate in the study\n\nExclusion Criteria:\n\n* Presence of stones in the gall bladder and bile ducts;\n* The presence of jaundice, cholestatic liver diseases, liver cirrhosis with decompensation;\n* Increased ALT, AST above the 3 upper limits of normal;\n* Hypersensitivity to the components of the drug Odeston;\n* Pregnancy and lactation;\n* Prolonged fasting and total parenteral nutrition;\n* Patients with symptoms of acute abdomen at the time of inclusion in the study;\n* Patients with symptoms of acute neurological pathology at the time of inclusion in the study and\u002For аcute cerebrovascular accident, a history of convulsive syndrome;\n* Presence of cancer;\n* Acute infectious diseases at the time of inclusion in the study;\n* Fever of any origin (above 37.5 C);\n* Patients with symptoms of heart failure;\n* Patients with symptoms of pulmonary failure;\n* Patients with symptoms of acute or chronic renal failure;\n* A decompensated form of diabetes;\n* Patients with signs of psychiatric disorders.","65 Years",{"count":47,"type":20},169,[49],"Chronic Cholecystitis","NOT_YET_RECRUITING","2024-07-17",{"date":53,"type":29},"2024-07-24",{"date":55,"type":20},"2024-08",{"date":57,"type":20},"2025-08",{"name":35,"class":36},15,""]